We are live on ! Find out more
CRNX icon

Crinetics Pharmaceuticals
CRNX

85 hedge funds and large institutions have $429M invested in Crinetics Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 33 increasing their positions, 15 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

233% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 6

120% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 15

20% more funds holding

Funds holding: 71 → 85 (+14)

0.16% more ownership

Funds ownership: 92.26% → 92.42% (+0.16%)

10% less capital invested

Capital invested by funds: $475M → $429M (-$46.5M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

Holders
85
Holders Change
+14
Holders Change %
+19.72%
% of All Funds
1.5%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.04%
New
20
Increased
33
Reduced
15
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$9.93M
2
DCM
Driehaus Capital Management
Illinois
+$8.07M
3
BlackRock
BlackRock
New York
+$4.38M
4
BBA
Baker Bros. Advisors
New York
+$4.38M
5
Morgan Stanley
Morgan Stanley
New York
+$2.02M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$24.6M
2
EAM
Eventide Asset Management
Massachusetts
-$13.2M
3
OM
Opaleye Management
Massachusetts
-$3.76M
4
IC
Ikarian Capital
Texas
-$784K
5
N
Nuveen
North Carolina
-$592K
Name Holding Trade Value Shares
Change 		Change in
Stake
CSS
76
Cubist Systematic Strategies
Connecticut
$16K +$16.3K +1,168 New
PCM
77
Penserra Capital Management
California
$10K +$10.5K +755 New
Royal Bank of Canada
78
Royal Bank of Canada
Ontario, Canada
$8K +$7.38K +530 +1,432%
PAM
79
Panagora Asset Management
Massachusetts
$5K +$4.51K +324 New
S
80
SignatureFD
Georgia
$4K +$3.94K +283 New
Daiwa Securities Group
81
Daiwa Securities Group
Japan
$1K +$864 +62 New
US Bancorp
82
US Bancorp
Minnesota
$1K +$878 +63 New
AIG
83
American International Group
New York
$222 -$6.28K -451 -3%
Walleye Capital
84
Walleye Capital
New York
$171 +$169K +12,100 New
OM
85
Opaleye Management
Massachusetts
– -$3.76M -240,000 Closed
IC
86
Ikarian Capital
Texas
– -$784K -50,000 Closed
CCM
87
CAAS Capital Management
New York
– -$561K -35,792 Closed
HS
88
HighVista Strategies
Massachusetts
– -$483K -30,845 Closed
AC
89
Athanor Capital
New York
– -$195K -12,459 Closed
AG
90
Aperio Group
California
– -$171K -10,910 Closed
PHK
91
Point72 Hong Kong
Hong Kong
– +$279 +20 +250%
1 2 3
4

CRNX Hedge Fund Activity: Q4 2020 in Review

85 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q4 2020, worth a combined $429M — down 9.8% from $475M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new CRNX positions and 6 closed out — a net gain of 14 holders — while 33 added to existing stakes and 15 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $9.93M. The largest seller was RA Capital Management, cutting an estimated $24.6M.

  • 85 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q4 2020, up from 71 in Q3 2020.
  • Funds reported $429M of Crinetics Pharmaceuticals stock for Q4 2020, down 9.8% quarter-over-quarter.
  • 20 funds opened new Crinetics Pharmaceuticals positions in Q4 2020 and 6 closed out, a net change of +14 holders.
  • The largest Crinetics Pharmaceuticals buyer in Q4 2020 was Point72 Asset Management, an estimated $9.93M added.
  • The largest Crinetics Pharmaceuticals seller in Q4 2020 was RA Capital Management, an estimated $24.6M sold.

Based on aggregated 13F filings for Q4 2020.